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A B S T R A C T
Thymidine phosphorylase (TP) is a catabolic enzyme in thymidine metabolism that is frequently
upregulated in many solid tumors. Elevated TP levels are associated with tumor angiogenesis, metastasis
and poor prognosis. Therefore, the use of TP inhibitors might offer a promising strategy for cancer
treatment. The tritylated inosine derivative 50-O-tritylinosine (previously designated KIN59) is a non-
competitive inhibitor of TPwhichwas previously found tobe instrumental for the crystallization of human
TP. A combination of computational studies including normal mode analysis, automated ligand docking
and molecular dynamics simulations were performed to deﬁne a plausible binding site for 50-O-
tritylinosine on human TP. A cavity inwhich 50-O-tritylinosine could ﬁtwas identiﬁed in the vicinity of the
Gly405–Val419 loop at a distance of about 11 A˚ from the substrate-binding site. In the X-ray crystal
structure, this pocket is characterized by an intricate hydrogen-bonding network in which Asp203 was
found to play an important role to afford the loop stabilization that is required for efﬁcient enzyme
catalysis. Site-directed mutagenesis of this amino acid residue afforded a mutant enzyme with a severely
compromised catalytic efﬁciency (Vmax/Km of mutant enzyme 50-fold lower than for wild-type TP) and
pronounced resistance to the inhibitory effect of 50-O-tritylinosine. In contrast, theD203Amutant enzyme
kept full sensitivity to the competitive inhibitors 6-aminothymineand 6-amino-5-bromouracil,which is in
line with the kinetic properties of these inhibitors. Our ﬁndings reveal the existence of a previously
unrecognized site in TP that can be targeted by small molecules to inhibit the catalytic activity of TP.
 2009 Elsevier Inc. All rights reserved.
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Thymidine phosphorylase (TP) is a key enzyme of the nucleo-
side salvage pathway [1] that catalyzes the reversible conversion of
thymidine and 20-deoxyuridine to their respective bases and a-D-Abbreviations: 6A5BU, 6-amino-5-bromouracil; 6AT, 6-aminothymine; 7-DX, 7-
deazaxanthine; BVDU, (E)-5-(2-bromovinyl)-20-deoxyuridine; CAM, chorio-allan-
toic membrane; dThd, thymidine; EDTA, ethylenediaminetetraacetic acid; KIN59,
50-O-tritylinosine; GST, glutathione S-transferase; HPLC, high-pressure liquid
chromatography; MD, molecular dynamics; MM-GBSA, molecular mechanics-
generalized Born surface area; NMA, normal mode analysis; PMSF, phenylmethyl-
sulfonylﬂuoride; RESP, restrained electrostatic potential; rmsd, root-mean-square-
deviation; SASA, solvent accessible surface area; TFT, 5-triﬂuorothymidine; TP,
thymidine phosphorylase; TP65, 9-[8-phosphonooctyl]-7-deazaxanthine; TPI, 5-
chloro-6-[1-(2-iminopyrrolidinyl)methyl]uracil hydrochloride; TS, transition state.
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doi:10.1016/j.bcp.2009.04.0112-deoxyribose-1-phosphate. TP not only recognizes natural 20-
deoxynucleosides but is also able to catalyze the phosphorolysis of
several nucleoside analogues endowed with antiviral or antitumor
activity, such as 5-triﬂuorothymidine (TFT), 5-(E)-(2-bromovinyl)-
20-deoxyuridine (BVDU) and 5-ﬂuoro-20-deoxyuridine [2–4]. In
addition to its catabolic role in the nucleoside salvage pathway, TP
is also implicated in tumor progression as it has been shown to
stimulate angiogenesis [5–8] and protect tumor cells from
apoptosis [9–11]. A wide range of tumors, including breast, colon
and oesophageal carcinomas overexpress TP, and high levels of TP
have been correlated with microvessel density, metastasis and
poor patient survival [10].
Thus, TP represents a promising chemotherapeutic target and
TP inhibitors may (i) improve the antiviral and antitumor activity
of certain nucleoside analogues, and (ii) inhibit the angiogenic and
anti-apoptotic activities of TP. During the last decade, several novel
classes of TP inhibitors have been developed [12]. Formore than 30
years, the reference TP inhibitors were 6-aminouracil derivatives
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(6A5BU) [13]. In 2000, Fukushima et al. reported on TPI (5-
chloro-6-[1-(2-iminopyrrolidinyl)methyl]uracil hydrochloride) as
one of the most effective TP inhibitors to date, with an IC50 value of
35 nM [14]. In fact, a combination of TPI and TFT (designated TAS-
102) is currently being evaluated in clinical trials for the treatment
of various solid tumors, including metastatic colon and breast
carcinomas [15,16].
Our research groups have described7-deazaxanthine (7-DX), the
ﬁrst purine derivative with inhibitory activity against TP and
angiogenesis in the ‘chickenchorioallantoicmembrane’ (CAM)assay
[17], and also TP65 (9-[8-phosphonooctyl]-7-deazaxanthine), the
ﬁrst multisubstrate inhibitor of TP that was shown to interact with
both the thymidine and the phosphate binding site of TP [18,19].
More recently,we identiﬁed thepurinenucleoside50-O-tritylinosine
as a novel TP inhibitor [20,21], in which the presence of the trityl
moiety was proven to be crucial for both its inhibitory activity
against TP and its anti-angiogenic effect in the CAM assay. 50-O-
Tritylinosine is also a rather unique TP inhibitor because (i) it
promotes the degradation of pre-existing immature vessels in the
CAM assay, and (ii) in contrast to all previously described TP
inhibitors, it inhibits TP in a non-competitive fashionwith respect to
both thymidine and phosphate. This latter ﬁnding implies that 50-O-
tritylinosine does not bind to the substrate-binding sites of TP, but
rather interacts with a novel, yet unknown, allosteric site of TP that
could also play a role in the biological activities of this protein.
It may be mentioned that diffraction-grade crystals of human
TP in complex with TPI [22] were only obtained after limited
treatment with trypsin, yielding two protein fragments consisting
of residues 12–408 and 411–482. The structure was solved at 2.7 A˚
resolution, revealing a single protomer in the asymmetric unit, but
the polypeptide stretch encompassing amino acids 407–414 could
not be determined. In contrast, no proteolysis was required and
well-ordered crystals with diffraction at 2.3 A˚ resolution were
obtained when both thymidine (2 mM) and 50-O-tritylinosine
(1 mM) were present under the crystallization conditions [23]. In
this latter structure, two dimers appeared in the asymmetric unit,
and residues 406–415 were visible as an arginine-rich surface loop
that extends across the active site cleft and appears to stabilize the
closed conformation of the enzyme and the dimer interface
through hydrogen bonds. Taking these two crystal structures
together, it is clear that the overall fold of human TP is similar to
that previously reported for E. coli TP [24,25] and comprises a large
a/b domain connected by three loops to a smallera domain. These
three loops act as a hinge that allows the motion of one domain
relative to the other so that the enzyme can interconvert from an
open, inactive form to a closed conformation that is catalytically
active. Intriguingly, although the presence of 50-O-tritylinosine
was instrumental for yielding good-quality diffracting crystals of
TP, no clear electron density was found for this non-competitive
inhibitor, which in light of these ﬁndings may be regarded as a
synthetic small-molecule, so-called ‘‘crystallization chaperone’’
[26]. For this reason, we have attempted to ﬁnd a plausible binding
site for 50-O-tritylinosine on human TP and to provide a rationale
for its behavior as a non-competitive inhibitor. Our proposal has
been indirectly validated by site-directed mutagenesis of Asp-203,
an amino acid that has turned out to be important not only for
selective inhibition of the enzyme by the 50-O-tritylinosine ligand
but also for full catalytic competence of the enzyme.
2. Methods and materials
2.1. Reagents
50-O-Tritylinosine (earlier designated KIN59) was synthesized
as described previously [20,27]. The synthesis of 6AT and 6A5BUwas performed as described [13,28]. Thymidine (dThd) and
thymine (Thy) were purchased from Sigma (St-Louis, MO). The
structural formulae of these compounds, as well as the reference
inhibitor TPI, are depicted in Fig. 1.
2.2. Molecular modeling
2.2.1. Normal mode analysis
The X-ray crystal structure of human TP (PDB code 2J0F) [22] at
2.31 A˚ resolution,was retrieved from the Protein Data Bank (http://
www.rcsb.org/pdb/). To probe the ﬂexibility of this enzyme, an
elastic networkmodel was used inwhich all non-hydrogen protein
atoms (within a cutoff of 10 A˚) were modeled as point masses and
Ca atoms were connected by springs representing the interatomic
force ﬁelds. Monomer A was analyzed as a large set of coupled
harmonic oscillators using the normal mode analysis, deformation
and reﬁnement (NOMAD-Ref) server [29] and default parameters.
The conformational changes were deduced by calculating the 10
lowest-frequency normal modes, which are those with the highest
amplitudes and those most often related to large-scale structural
rearrangements in proteins. Each mode was explored in its two
opposite directions, thus resulting in a series of conformations
different from the crystallographic structure within a maximum
root-mean-square deviation (rmsd) value of 2 A˚.
2.2.2. Quantummechanical methods, molecular mechanics force ﬁeld
and atom point charges
The geometry of 50-O-tritylinosine was ﬁrst reﬁned by means of
the semi-empirical quantummechanical programmolecular orbital
package (MOPAC) [30], using the AM1 Hamiltonian and PRECISE
stopping criteria, and further optimized using a restricted Hartree–
Fock (RHF) method and a 6–31G(d) basis set, as implemented in the
ab initio program Gaussian 03 [31]. The resulting wavefunctions
were used to calculate electrostatic potential-derived (ESP) charges
employing the restrained electrostatic potential (RESP) methodol-
ogy, as implemented in the assisted model building with energy
reﬁnement (AMBER) suite of programs (http://amber.scripps.edu/).
The missing bonded and nonbonded parameters were assigned, by
analogy or through interpolation from those already present in the
AMBERdatabase, inawayconsistentwiththeAMBER forceﬁeld [32].
The geometry and atom point charges for the transition state (TS) of
the phosphorolysis reactionwere retrieved frompreviouswork [33].
2.2.3. Docking of 50-O-tritylinosine into human TP
A box encompassing both the active site and the loop regions
was deﬁned for the exploration of possible binding modes. The
Lamarckian genetic algorithm implemented in AutoDock 3.0.5
[http://www.scripps.edu/pub/olson-web/doc/autodock] was then
used to generate docked conformations of this inhibitor in either
the original protein structure or those derived from the NMA by
randomly changing the overall orientation of the molecule as well
as the torsion angles of all rotatable bonds. Default settings were
used except for number of runs, population size, and maximum
number of energy evaluations, which were ﬁxed at 250, 100, and
250,000, respectively. Rapid intra- and intermolecular energy
evaluation of each conﬁguration was achieved by having the
receptor’s atomic afﬁnity potentials for aliphatic and aromatic
carbon, oxygen, nitrogen, and hydrogen atoms precalculated in a
three-dimensional grid with a spacing of 0.375 A˚. A distance-
dependent dielectric function was used in the computation of
electrostatic interactions.
2.2.4. Molecular dynamics (MD) simulations
TheMD simulations were carried out using the AMBER 8.0 suite
of programs [34]. A model of D203A TP was constructed using the
mutagenesis module available in the molecular graphics program
Fig. 1. Chemical structures of relevant TP inhibitors.
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D203A TP with the transition state (TS) of the reaction [33] and of
wild-type TP with KIN59 were neutralized by addition of sodium
ions [35] and immersed in truncated octahedrons of TIP3P water
molecules [36]. Periodic boundary conditions were applied and
electrostatic interactions were treated using the smooth particle
mesh Ewald method [37] with a grid spacing of 1 A˚. The cutoff
distance for the non-bonded interactions was 9 A˚. The SHAKE
algorithm [38] was applied to all bonds and an integration step of
2.0 fs was used throughout. Solvent molecules and counterions
were relaxed by energy minimization and allowed to redistribute
around the positionally restrained solute (25 kcal mol1 A˚2)
during 50 ps of MD at constant temperature (300 K) and pressure
(1 atm). These initial harmonic restraints were gradually removed
and the resulting systems were allowed to equilibrate further in
the absence of any restraints for 10.0 ns during which system
coordinates were collected every 2 ps for further analysis.
2.2.5. MM-GBSA binding calculations
The binding free energy describing protein-ligand associations
is the difference between the free energy, G, of the complex and
that of the respective binding partners, in our case the wild-type
protein (TP) and the transition state of the reaction (TS), calculated
over a series of snapshots (i) taken from the MD trajectory
Gbind ¼ GðTPTSÞðiÞ  ðGTPðiÞ þ GTSðiÞÞ (1)
The value of G for each species was calculated using the
following energy decomposition scheme, which is implemented in
the molecular mechanics/generalized Born/surface area (MM–
GBSA) method within AMBER 8 (script mm_pbsa.pl) [39,40]:
G ¼ Egas þ Gsol  TS
Egas ¼ Eint þ Eele þ Evdw
Eint ¼ Ebond þ Eangle þ Etorsion
Gsol ¼ GGB þ Gnonpolar
Gnonpolar ¼ gSASA
(2)
Egas is the gas-phase energy, which is calculated using the
AMBER force ﬁeld [41,42] as the sum of internal energies (Eint),
encompassing bond lengths (Ebond), bond angles (Eangle) and
torsional angles (Etorsion), and coulombic (Eele) and van der Waals
(Evdw) non-bonded energies. The solvation free energy, Gsol, is
decomposed into polar and nonpolar contributions: the polar
contribution (GGB) is calculated by solving the generalized Bornequation [43] using dielectric constants of 1 and 78.5 for solute
and solvent, respectively, whereas the nonpolar contribution,
Gnonpolar, is estimated from the solvent accessible surface area
(SASA) [44], which is determined using a water probe with a
radius of 1.4 A˚. The surface tension constant g was set to
0.005 kcal/mol/A˚2. T and S are the temperature and the total
solute entropy, respectively. S is typically estimated on the basis
of classical statistical formulae and NMA of representative
snapshots of energy minimized structures from a MD trajectory.
In the present investigation this cumbersome procedure was
obviated so that, in a ﬁrst approximation, the solute entropy
estimates were not included in the calculation of the free energy
changes by assuming, on the basis of previous work [45], that its
contribution to DGbind would be negligible.
On the other hand, the use of a single trajectory to calculate
Gbind is conducive to a much better agreement with the
experimental data than when multiple trajectories are used
[46]. It is then expected that, by using a single trajectory, error
cancellation will overcome the insufﬁcient sampling of the
conformational space [45,47].
2.3. Site-directed mutagenesis of human TP
The pMOAL-10T vector containing the human TP gene (fused to
glutathione S-transferase [GST]) was described and kindly
provided by Prof. R. Bicknell (Oxford, UK) [48]. The mutant TP
enzyme containing the D203A mutation was derived from this
vector. Site-directed mutagenesis was performed using the Quick
Change site-directed mutagenesis kit (Stratagene, Westburg,
Leusden, The Netherlands) according to manufacturer’s instruc-
tions. The oligonucleotide primers that were used are 50 cgg aat cct
ata tgc agc cag agc tgt gac agc cac cgt gg-30 and its reverse primer
(Invitrogen, Merelbeke, Belgium). After linear ampliﬁcation of the
plasmid using Pfu DNA polymerase (Stratagene) in a temperature
cycler program (30 min at 95 8C followed by 20 cycles of 30 min at
95 8C, 1 min at 55 8C and 12 min at 68 8C), wild-type (methylated)
plasmid was digested with DpnI restriction enzyme (Stratagene)
and the mutant (unmethylated) DNA was transformed into E. coli
XL1-Blue super competent cells (Stratagene). The presence of the
desired mutation in the TP gene was conﬁrmed by sequencing on
an ABI Prism 3100 sequencer (Applied Biosystems, Foster City, CA),
using the ABI Prism Big Dye terminator cycle sequencing ready
reaction kit (Applied Biosystems).
Fig. 2. Scheme depicting the most relevant hydrogen bonds that contribute to loop
stabilization in the vicinity of Asp-203. For simplicity, only the atoms of one water
molecule are shown.
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The pMOAL-10T vector containing the wild-type TP or the
mutant D203A TP was transfected into E. coli BL21(DE3)pLysS.
Bacteria were grown overnight at 37 8C in 2YT medium containing
ampicillin (Bristol Myers Squibb, Brussels, Belgium) (100mg/mL)
and chloramphenicol (Sigma) (100mg/mL), diluted 1:10 in fresh
medium and further incubated for 5 h at 27 8C. Then isopropyl-b-
D-thiogalactopyranoside (IPTG) (Sigma) was added to a ﬁnal
concentration of 0.1 mM to induce the expression of the GST-TP
fusion protein. After a further incubation for 15 h at 27 8C, the cells
were pelleted (10,000  g for 10 min at 4 8C) and resuspended in
lysis buffer (50 mM Tris, pH 7.5, 1 mM dithiothreitol, 5 mM EDTA,
10% glycerol, 1% Triton X-100, 0.1 mM phenylmethylsulfonyl-
ﬂuoride [PMSF] and 0.15 mg/mL lysozyme). The bacterial suspen-
sions were passed through the SLM Aminco French Pressure Cell
Press (Beun de Ronde, La Abcoude, The Netherlands) and
centrifuged at 20,000  g for 15 min at 4 8C. The GST-TP fusion
protein was further puriﬁed from the supernatant using Glu-
tathione Sepharose 4B (GE Healthcare, Little Chalfont, Buckin-
ghamshire, UK), following the instructions of the manufacturer.
Brieﬂy, a 50% glutathione-agarose slurrywas added to the bacterial
supernatant, incubated for 30 min at 4 8C, and then washed three
times with 10 bed volumes (7.5 mL) of lysis buffer without
lysozyme and PMSF. Bound proteinswere eluted in 50 mMTris (pH
8.0) containing 0.1% Triton X-100 and 10 mM glutathione. Protein
content of the puriﬁed fractions was determined using Bradford
reagent (Sigma, St-Louis, MO).
2.5. TP enzyme assays
The conversion of dThd to thymine was measured by high-
pressure liquid chromatography (HPLC) analysis. To determine the
conversion activity, different amounts (ranging from 20 to
0.10 mg/500 mL reaction mixture) of wild-type or mutant D203A
TP were initially incubated with 100 mM of dThd in TP-buffer
(10 mM Tris–HCl, pH 7.6, 1 mM EDTA, 2 mM KH2PO4/K2HPO4 and
150 mM NaCl). At different time points (i.e. 0, 15, 30, 60 min),
100 mL aliquots of the reaction mixtures were withdrawn and
heated at 95 8C for 3 min to inactivate the enzyme. DThd was
separated from thymine on a reverse-phase RP-8 column (Merck,
Darmstadt, Germany) and quantiﬁed by high-pressure liquid
chromatography (HPLC) analysis (Alliance 2690, Waters, Milford,
MA). The separation was performed by a linear gradient from 98%
buffer B (50 mMNaH2PO4 and 5 mMheptane sulfonic acid, pH 3.2),
to 20% buffer B + 80% acetonitrile (8 min 98% buffer B + 2%
acetonitrile; 5 min linear gradient of 98% buffer B + 2% acetonitrile
to 20% buffer B + 80% acetonitrile; 10 min 20% buffer B + 80%
acetonitrile, followed by equilibration at 98% buffer B + 2%
acetonitrile). Retention times of thymine and dThd were respec-
tively 5.1 and 10.8 min. UV-based detection was performed at
267 nm.
In the kinetic assays, the Km and Vmax of wild-type and mutant
D203A TP were determined at varying concentrations of dThd,
while the concentration of inorganic phosphate was kept constant
at 25 mM. In these experiments, wild-type TP was used at a
concentration of 0.5 mg/500mL reactionmixture in the presence of
5, 3, 2, 1, 0.5 and 0.2 mM dThd, while the mutant D203A TP was
tested at a concentration of 10 mg/500 mL reaction mixture in the
presence of 40, 30, 20, 15 and 10 mM dThd. Incubation was
performed for 15 min. At this time point, the reaction still
proceeded linearly.
To evaluate the inhibitory activity of 50-O-tritylinosine, 6AT and
6A5BU several concentrations of these TP inhibitors were added to
the reaction mixtures containing 100mM (for wild-type TP) or
2.5 mM (for mutant D203A TP) of dThd. Wild-type TP and mutantD203A TP were used at a concentration of 0.5 and 10 mg/500 mL
reaction mixture, respectively. The mixtures were incubated for
15 min. The amount of thymine formed was determined by HPLC
analysis as described above.
3. Results and discussion
3.1. Proposal of a binding mode for KIN59 on human TP
Inspection of the Gly-405–Val-419 loop (which was clipped in
the structure of Norman et al. [22]), in the crystallographic
structure of El Omari et al. [23], revealed an intricate hydrogen-
bonding network, the most relevant part of which is schematically
represented in Fig. 2: (i) the backbone NH of Arg-408 is hydrogen-
bonded to a well-deﬁned water molecule (W98 in subunit A,
designatedWAT1) that is ﬁxed in place by two additional hydrogen
bonds: one with the backbone carbonyl of Gly-149 and another
with one carboxylate oxygen from Asp-203, a residue that is
situated at the terminus of a-helix 9, (ii) the same carboxylate
oxygen of Asp-203 forms a good hydrogen bondwith the backbone
NH of Gly-149, which is next to Leu-148, a residue whose side-
chain provides a hydrophobic surface for interaction with the
pyrimidine base of both the dThd substrate and competitive
inhibitors such as TPI, (iii) the guanidinium group of Arg-408
establishes two strong hydrogen bonds with the carboxylate
oxygens of Asp-156 (not shown) and also a water-mediated (W80
in subunit B, designatedWAT2) hydrogen bondwith the other Asp-
203 carboxylate oxygen, (iv) the carbonyl groups of the backbones
of Asp-203 and Arg-408 are both accepting a hydrogen bond from a
common water molecule (designated WAT3); (v) the guanidinium
group of Arg-410 is partly exposed to the solvent but also engaged
in an intersubunit hydrogen bond with the carbonyl group of Ser-
65 (not shown); and (vi) the backbone CO and NH groups of Ala-
411 in one protomer establish two good hydrogen bonds with the
side-chain carboxamide of Gln-67 in the neighboring subunit (not
shown). Thus, it appears that the Gly-405–Val-419 loop consists of
closely interacting amino acids that contribute to the stabilization
of the closed conformation of the enzyme (the only state that
presents the integral active site) by helping to hold the a and a/b
domains together.
When the surroundings of this loop were probed for plausible
binding sites for 50-O-tritylinosine using the reported X-ray crystal
structure and the automated docking program AutoDock, no
convincing solutions were found. 50-O-Tritylinosine is a rather
lipophilic compound possessing a bulky trityl moiety for which no
electron density emerged in the diffraction maps. However, the
molecule clearly helped stabilize the conformation of this loop in
the crystal lattice [23]. We reasoned this might be due to ligand
Fig. 3. Proposed binding site for 50-O-tritylinosine (previously designated KIN59 [20]) in human TP. (a) Ribbon representation of the enzymewith protein residues enveloped
by a semitransparant solvent-accessible surface. Carbon atoms of 50-O-tritylinosine are colored in magenta. (b) Enlarged view of the framed area shown in (a). Some of the
protein residues relevant to the discussion have been labeled, and their side chains are shown as sticks.
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hydrophobic collapse. We therefore decided to further focus on
some prior conformational state(s) of the enzyme for our docking
studies. Since open and closed TP conformations are connected by
hinge-dependent interdomain motions [33], as is also the case in
the related pyrimidine nucleoside phosphorylase (PyNP) [49], we
used normal mode analysis (NMA) to reproduce this motion and
generate a series of intermediate protein conformers that could
help in the identiﬁcation of a region capable of lodging the
hydrophobic and polar substituents of 50-O-tritylinosine.
By following the lowest frequency mode, a cavity was
generated in the vicinity of the Gly-405–Val-419 loop that was
mainly lined by the side chains of apolar residues Leu-155, Val-166
and Ile-167, and positively charged residues Arg-146 and Arg-408,
all of which can provide good anchoring points for the crucial trityl
group of 50-O-tritylinosine. Indeed, the automated docking
program could ﬁnd satisfactory docking solutions for 50-O-
tritylinosine making use of this hydrophobic cavity. Thus, in the
optimal solution, and following complex relaxation using mole-
cular dynamics (MD), the guanidinium of Arg-146 is found
stacking on top of one of the phenyl rings, which in turn makesFig. 4. Conversion of thymidine to thymine by wild-type and mutant D203A TP as a fun
100mM.van der Waals contacts with the side chains of Leu-155 and Val-
166, whereas another phenyl of the trityl group interacts with the
side chains of Val-166 and Ile-167. As regards the remaining part of
the inosine nucleoside, the 30 hydroxyl of the ribose is engaged in a
hydrogen bond with the carboxamide group of Gln-187 (not
shown), whereas the hypoxanthine moiety gets sandwiched
between the tip of the Gly-405–Val-419 loop and the C-terminus
of helix 9. In this location, the heteroaromatic ring partially sits on
top of the side-chain methyl of Ala-200 (not shown), N3 is close to
Ne of Arg-146 and N1 is oriented towards the carboxylate of Asp-
203 and the isopropyl of Val-204 (not shown) (Fig. 3).
This docking proposal accounts for the mechanism of non-
competitive inhibition, insofar as 50-O-tritylinosine does not make
use of the dThd or phosphate binding sites, and is qualitatively
consistent with the known structure-activity relationship for this
class of 50-O-tritylinosines [50]. Indeed, it is known that one of the
phenyl rings in the essential trityl substituent can accept a chlorine
atom at the para position leading to enhanced potency, and also
that incorporation of a methylcyclopropyl or methylcyclohexyl
substituent at the N1 position of hypoxanthine results in increased
inhibitory activity. The former ﬁnding can be explained becausection of time and at different enzyme concentrations. The dThd concentration was
Fig. 5. Detail of the active site of wild-type TP containing the transition state of the
reaction (black dashes represent bonds that are being broken/created). The most
relevant residues have been labeled and hydrogen bonds are shown as yellow
dashed lines.
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made up by Leu-155, Val-166, and Ile-167 whereas the latter may
originate from improved hydrophobic interactions between the
cycloalkyl substituent and the side chain of Val-204.
Given the central role ascribed to Asp-203 in the stabilization of
the Gly-405–Val-419 loop over the active-site cleft in the closed
conformation, we decided to mutate this residue to alanine in
order to assess the impact of this amino acid replacement on both
enzyme activity and modulation of catalysis by TP inhibitors.
3.2. Enzymatic activity and kinetic parameters of wild-type and
mutant D203A TP
The enzymatic activities of puriﬁed recombinant wild-type and
mutant D203A TP were compared by using different amounts of
enzyme (0.5 and 0.1 mg/500mL reaction mixture for wild-type TP
and 20, 5 and 0.5 mg/500mL reaction mixture for mutant D203A
TP). The enzymes were incubated for 0, 15, 30 and 60 min in the
presence of 100 mM of dThd (Fig. 4). The mutant D203A TP
converted markedly less substrate to thymine, as compared to the
corresponding wild-type enzyme. The reaction proceeded linearly
for up to at least 60 min at the lower TP concentrations and up to
15 min at the highest enzyme concentrations. Based on the
enzyme concentrations used, it was estimated that the mutant
D203A TP converts dThd to thymine at least 20-fold less efﬁciently
than wild-type enzyme in the presence of 100 mM dThd (Fig. 4).
Thus, the mutation of aspartic acid to alanine at amino acid
position 203 of TP resulted in a signiﬁcant loss of efﬁciency to
perform the phosphorolysis of dThd. Therefore, higher concentra-
tions were used for the mutant D203A enzyme than wild-type TP
to obtain reliable enzyme kinetic data that could be compared.
To determine the kinetic parameters for wild-type and mutant
D203A TP the enzyme concentrations used were 0.5 mg/500 mL
reaction mixture and 10 mg/500 mL reactionmixture, respectively.
Under these experimental conditions, the enzyme-catalytic
activity proceeded linearly during the incubation (15 min) time.
Both enzymes were incubated in the presence of varying
concentrations of dThd at a saturating concentration of inorganic
phosphate. The Km value of the mutant D203A TP (9.8 mM) proved
to be 23 times higher than that of the wild-type enzyme (Km:
414 mM), which suggests a markedly diminished afﬁnity of theFig. 6. Time evolution of the overall interaction energy between the transition state of
molecular dynamics simulations.mutant enzyme for its natural substrate dThd. Moreover, a 2.5-fold
reduction in the Vmax value (1026 nmol/min/mg for wild-type TP
versus 400 nmol/min/mg for mutant D203A TP) indicated that the
mutation also affected (albeit to a lesser extent) the rate of dThd
phosphorolysis (Table 1). Overall, the phosphorolytic capacity of
the mutant D203A TP proved to be 60-fold lower than that of
wild-type TP using dThd as the natural substrate.
3.3. Simulation of the transition state of the reaction in the wild-type
and mutant D203A TP enzymes
In light of the preceding results we sought to determine the
structural basis for the decrease in catalytic performance of the
mutant D203A TP relative to the wild-type enzyme using
computational methods. Since the geometry of the phosphorolysisthe reaction and either wild-type (blue) or D203A (magenta) human TP during the
Table 1
Kinetic parameters of human wild-type and mutant D203A TP.
Km
a (mM) Vmax
b (mmol/mg protein/min) Vmax/Km
c
Wild-type TP 414  96 1026  460 2.48
D203A mutant TP 9828  3200 400  136 0.041
Enzyme activity is expressed as the amount of dThd converted to thymine (mmol/
mg protein/min). Values are presented as means  standard deviation of at least
three independent experiments.
a Km is the Michaelis–Menten constant of the enzyme for dThd.
b Vmax is the maximum velocity of the enzyme reaction.
c Vmax/Km ratio or catalytic phosphorolytic capacity of the enzyme.
Fig. 7. Effect of the inhibitors 50-O-tritylinosine (panel A), 6AT (panel B) and 6A5BU
(panel C) on the enzymatic activity of TP. Wild-type and mutant D203A TP were
incubated at 37 8C for 15 min at an enzyme concentration of 0.5 and 10mg/500 mL
reaction mixture, respectively. The dThd concentration in the assays was 100mM
(WT TP) or 2500mM (mutant D203A TP) to compensate for the different Km values
of both enzymes. The conversion of dThd to thymine in the presence of different
amounts of inhibitorswas determined byHPLC analysis. Values are presented as the
mean of at least three different independent experiments  standard error.
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detail [33], unrestrained MD simulations of each enzyme in the
presence of an active site-bound TS were undertaken to analyze
the relative binding afﬁnities in the two complexes.
In the wild-type enzyme the TS appears to be stabilized by a
number of interactions involving both polar and apolar active-site
residues (Fig. 5): (i) the pyrimidine ring gets sandwiched between
the side chains of Tyr-199 and Leu-148, on one side, and that of Ile-
218 on the other side, and places themethyl group in the vicinity of
Val-241 (not shown); (ii) the O2 and O4 of thymine accept
hydrogen bonds from the amino group of Lys-221 and the
guanidinium group of Arg-202, respectively, whereas the hydroxyl
of Ser-217 accepts a hydrogen bond from N3 and the imidazole
ring of His-116makes a bifurcated hydrogen bondwith N1 and O2;
(iii) the O50 of the deoxyribose accepts a H-bond from the hydroxyl
of Thr-151 and donates one to the carbonyl of the backbone of Gly-
119 while the backbone NH of Thr-154 hydrogen bonds to O30 of
the deoxyribose, which in turn donates another H-bond to the
phosphate, precisely to the same oxygen (OP1) that accepts a
second H-bond from the hydroxyl of Thr-154; and (iv) the
phosphate OP3 accepts two hydrogen bonds, one from the amino
group of Lys-115 and another from the hydroxyl of Ser-117 (not
shown). This elaborate hydrogen-bonding pattern, which is
maintained during the whole length of the MD simulation,
stabilizes the TS geometry and facilitates the nucleophilic attack
of the phosphate O2P onto the sugar ring atom C10.
By hydrogen-bonding to the NH of Gly-149, the carboxylate of
Asp-203 was thus seen to play a crucial role in facilitating the
correct placement of the side-chain of Leu-148. This amino acid
residue has been previously shown to be essential for TP activity
[7], most likely because it provides a hydrophobic platform for the
stacking of both the phenol ring of Tyr-199 (which is ﬁxed in place
with the aid of a hydrogen bond from the hydroxyl group to the
backbone carbonyl of Arg-146) and the pyrimidine base of the
substrate and competitive inhibitors. In fact, the major difference
observed within the slightlymore open active site in the simulated
TS-TP complex for the mutant D203A enzyme involved the
positioning of Leu-148 and when the MM-GBSA method was
used to calculate the binding energies of the TS within both
enzymes along the simulation period, the binding energy
corresponding to the mutant D203A TP was indeed found to be
consistently decreased relative to the wild-type protein (Fig. 6).
Moreover, the loss of binding energy originated in the van der
Waals term because the electrostatic and desolvation components
were virtually identical (data not shown). Therefore, even though
these binding energy values have to be regarded as qualitative
rather than quantitative (since entropic effects, which are
cumbersome to compute and subject to large numerical errors,
were not included in the calculation), the trend is very clear and is
in agreement with the experimental ﬁndings: the loss of the
hydrogen bond between the carboxylate of Asp-203 and the
backbone NH of Gly-149 results in a repositioning of the side chain
of Leu-148 and in a more open active site, both of which aredetrimental for dThd binding, TS stabilization and efﬁcient
catalysis.
3.4. Inhibition of wild-type and mutant D203A TP by competitive and
non-competitive inhibitors
It has been suggested that mouse liver TP contains more than
one allosteric (i.e. thymine binding) site, and that when thymine is
bound to one of these sites, the enzyme is inhibited [51]. We found
thymine (100mM) to be inhibitory to the human TP-catalysed
hydrolysis of 100 mM dThd, but thymine had no effect on the
inhibitory activity of 50-O-tritylinosine (200mM and 100 mM)
(data not shown), making it unlikely that 50-O-tritylinosine may
bind to one of such potential thymine-binding sites.
However, we previously showed that 50-O-tritylinosine inhibits
TP in a non-competitive fashion [20]. If Asp-203 is part of a putative
allosteric site to which this inhibitor binds one would expect that
mutation of this amino acid residue to alanine would affect the
inhibitory activity of this compound against TP. To test this
hypothesis, wild-type and mutant TP enzymes were incubated for
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tions of either the non-competitive inhibitor 50-O-tritylinosine or
the known competitive inhibitors 6AT and 6A5BU. As shown in
Fig. 7, 50-O-tritylinosine was completely unable to inhibit the
enzymatic activity of the D203A mutant TP regardless of the
concentrations used (100, 50 and 25mM) whereas a concentra-
tion-dependent inhibition of the wild-type enzyme was observed
(Fig. 7, panel A). In sharp contrast, the competitive inhibitors 6AT
and 6A5BU, which have been shown to interact with the dThd-
binding site of TP [20], were able to dose-dependently decrease the
enzymatic activity of wild-type and mutant D203A TP to a similar
extent (Fig. 7, panels B and C) (6AT and 6A5BU inhibitor
concentrations used: 50, 25 and 5 mM for wild-type TP andFig. 8. ClustalWmultiple sequence alignment of the amino acid sequences of mouse, rat,
substitutions, respectively. Asp-203 is shown in red, amino acids participating in sub
tritylinosine (previously designated KIN59 [20]) are shown in green.1250, 625 and 125 mM for mutant D203A TP in the presence of
100 mM dThd for wild-type TP and 2500 mM dThd for mutant
D203A TP). These ﬁndings are compatible with the view that
binding of dThd, 6AT and 6A5BU to the active site is similarly
compromised in the mutant enzyme relative to the wild-type TP
whereas the putative allosteric site for 50-O-tritylinosine binding is
no longer present on the mutant D203A TP due to loop disruption.
3.5. Concluding remarks
Earlier site-directed mutagenesis studies on TP have conﬁrmed
the importance for catalysis of Lys-115, Leu-148, Arg-202, Ser-217,
and Lys-221 [7,8]. All of these are active-site residues directlyhuman and E. coli TP. (*) identical residues, (.) and (:) conserved and semi-conserved
strate binding are shown in blue, and residues proposed to be involved in 50-O-
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phosphate) and the TS, as explained above. Asp-203, on the other
hand, is positioned at the end of an a-helix and extends its side
chain towards a solvent region comprised between the glycine-
rich 144–153 loop and the more mobile arginine-rich 406–415
loop. In this location, the Asp-203 carboxylate can accept two
hydrogen bonds: one from the backbone NH of Gly-149 in the
former loop (Figs. 2 and 5) and a second one from awatermolecule
that is, in turn, hydrogen bonded to the guanidinium of Arg-408 in
the latter loop (Fig. 2). In addition, the Asp-203 carbonyl can also
make a water-mediated hydrogen bond with the carbonyl of Arg-
408 (Fig. 2). It thus appears that Asp-203 plays a crucial role in loop
stabilization, and this action is important for both catalysis and
inhibition by the non-competitive inhibitor 50-O-tritylinosine.
50-O-Tritylinosine has been described previously as an inhibitor
of both human and bacterial TP enzymes [20,21]. Given the non-
competitive nature of this inhibition, this purine riboside
derivative was not expected to interact directly with either the
pyrimidine nucleoside-binding or phosphate-binding site of the
enzyme. On the contrary, this novel inhibitory mechanism was
indicative of the possible existence of a yet unidentiﬁed allosteric
site in the enzyme. Nonetheless, a crystal structure of human TP
produced in the presence of 50-O-tritylinosine revealed no traces of
this inhibitor neither in the active site, which was occupied by the
reaction product, thymine, nor anywhere else.
By using a combination of NMA, docking and MD simulation
methods, a location for this binding site is now proposed that relies
on the loop stabilization brought about by Asp-203. The site-
directed mutant D203A TP, which was constructed to assess the
importance of this residue, displayed a 60-fold reduction in
phosphorolytic capacity (Vmax/Km) relative to the wild-type
enzyme. Importantly, both wild-type and mutant TP were
inhibited to a similar extent by the competitive inhibitors 6AT
and 6A5BU whereas the non-competitive inhibitor 50-O-tritylino-
sine lost its inhibitory activity against the mutant D203A enzyme.
These data thus support a role for Asp-203 in loop stabilization,
which is important for catalytic activity, as well as for creating a
rather unique binding site for 50-O-tritylinosine. A multiple
sequence alignment of human, mouse, rat and E. coli TP (Fig. 8)
shows that Asp-203 is highly conserved during evolution, which
reinforces the idea that this amino acid may indeed be crucial for
the biological activities of TP.We previously hypothesized that this
putative allosteric site might be involved in the angiogenic activity
of TP [20,21]. Therefore, further investigations on the angiogenic
and anti-apoptotic properties of the mutant D203A enzyme would
be warranted.
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